Replimune Group (NASDAQ:REPL) Price Target Raised to $14.00

Replimune Group (NASDAQ:REPL) had its price objective hoisted by Piper Sandler from $13.00 to $14.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

REPL has been the topic of a number of other research reports. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $3.00 to $13.00 in a report on Monday, October 20th. JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target for the company in a report on Monday, October 20th. Finally, Wedbush lifted their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Replimune Group has an average rating of “Hold” and an average target price of $10.00.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $7.75 on Thursday. The firm’s fifty day simple moving average is $8.77 and its 200-day simple moving average is $7.22. Replimune Group has a 12 month low of $2.68 and a 12 month high of $14.80. The stock has a market capitalization of $639.92 million, a price-to-earnings ratio of -2.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 6.31.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. As a group, equities analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,248 shares of the company’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $65,956.80. Following the sale, the insider owned 139,685 shares of the company’s stock, valued at approximately $1,271,133.50. This represents a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 25,625 shares of company stock valued at $257,607. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Saturn V Capital Management LP acquired a new position in Replimune Group in the 2nd quarter valued at about $1,198,000. Squarepoint Ops LLC grew its holdings in shares of Replimune Group by 394.0% during the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock worth $631,000 after buying an additional 54,178 shares in the last quarter. Nan Fung Trinity HK Ltd. purchased a new stake in shares of Replimune Group during the second quarter worth about $4,325,000. Los Angeles Capital Management LLC acquired a new position in shares of Replimune Group in the second quarter valued at approximately $403,000. Finally, TD Asset Management Inc lifted its stake in shares of Replimune Group by 18.7% during the second quarter. TD Asset Management Inc now owns 327,452 shares of the company’s stock valued at $3,042,000 after buying an additional 51,600 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.